Online citations, reference lists, and bibliographies.
← Back to Search

Luminal B Breast Cancer: Molecular Characterization, Clinical Management, And Future Perspectives.

F. Ades, D. Zardavas, I. Bozovic-Spasojevic, L. Pugliano, D. Fumagalli, E. de Azambuja, G. Viale, C. Sotiriou, M. Piccart
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Gene expression profiling has reshaped our understanding of breast cancer by defining and characterizing four main intrinsic molecular subtypes: human epidermal growth factor receptor 2-enriched, basal-like, luminal A, and luminal B subtypes. Luminal B breast cancer has been reported to have lower expression of hormone receptors, higher expression of proliferation markers, and higher histologic grade than luminal A. It also exhibits worse prognosis and has a distinct profile of response to hormone therapy and chemotherapy. Although luminal cancers share similarities, the studies conducted in recent years using next-generation sequencing technology show that luminal A and B breast cancers should be perceived as distinct entities, with specific oncogenic drivers, rather than more proliferative varieties of luminal tumors. This review discusses the definition and molecular characterization of luminal B breast cancer and presents the available clinical evidence for chemotherapy and endocrine therapy patterns of response. It also provides an overview of ongoing research on molecularly targeted agents for this disease.
This paper references
10.1200/JCO.2007.11.9453
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
G. Viale (2007)
10.1016/j.canlet.2008.10.005
Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity.
Christine L. Hostetter (2009)
10.1200/JCO.2012.43.7251
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
D. Yardley (2013)
10.1006/EXCR.2001.5430
Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells.
I. H. Hamelers (2002)
Comprehensive molecular portraits of human breast tumours
Aleix Prat Aparicio (2012)
10.1200/JCO.2013.31.15_SUPPL.LBA509
Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
G. Hortobagyi (2013)
10.1073/pnas.0932692100
Repeated observation of breast tumor subtypes in independent gene expression data sets
T. Sørlie (2003)
10.1016/J.CCR.2006.10.009
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
K. Chin (2006)
10.1093/jnci/djp082
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
M. Cheang (2009)
10.1200/JCO.2011.29.27_SUPPL.289
A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC).
F. André (2011)
10.1093/annonc/mdq738
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
G. Viale (2011)
10.1038/nrc3090
Cyclin D as a therapeutic target in cancer
E. Musgrove (2011)
10.1200/JCO.2010.31.6950
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
M. Ellis (2011)
Immunohistochemical surrogate markers of breast
R Bhargava
Polychemotherapy for early breast cancer: an overview of the randomised trials
M. Clarke (1998)
10.1038/nm.2305
Cancer epigenetics reaches mainstream oncology
M. Rodríguez-Paredes (2011)
10.1007/s10549-009-0499-6
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
J. J. Ronde (2009)
10.1158/0008-5472.CAN-09-3746
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
N. Turner (2010)
Gene-expression signatures in breast cancer.
P. Helmbold (2003)
10.1200/JCO.2005.01.4829
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
M. Dowsett (2005)
10.1097/CCO.0b013e328358a2b5
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2−) breast cancers?
D. Zardavas (2012)
10.1093/annonc/mdr304
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch (2011)
10.1016/J.GHIR.2006.06.005
Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
A. Juncker-Jensen (2006)
10.1093/annonc/mds430
Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.
G. Cancello (2013)
10.1200/JCO.2010.34.4879
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
T. Miller (2011)
10.1016/j.steroids.2011.02.025
Association between breast cancer subtypes and response to neoadjuvant anastrozole
A. Dunbier (2011)
10.1056/NEJMOA041588
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
S. Paik (2004)
10.1186/bcr3219
Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways
R. Iwanaga (2012)
10.1002/gcc.20366
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer
A. Bergamaschi (2006)
10.1002/emmm.201100121
ZNF703 gene amplification at 8p12 specifies luminal B breast cancer
F. Sircoulomb (2011)
AMeta-Analysis on the Interaction between HER-2 Expression and Response to EndocrineTreatment in Advanced Breast Cancer
M. Laurentiis (2005)
10.1158/0008-5472.SABCS12-S1-6
Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)
R. Finn (2012)
10.1200/JCO.2001.19.18.3808
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
M. Ellis (2001)
10.1158/0008-5472.SABCS10-S1-4
Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)
P. Kaufman (2010)
10.1093/JNCI/DJK020
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
M. Dowsett (2007)
10.1200/JCO.2012.45.3639
Designing transformative clinical trials in the cancer genome era.
S. Sleijfer (2013)
10.1128/MCB.00118-10
Genome-Wide Analysis of Estrogen Receptor α DNA Binding and Tethering Mechanisms Identifies Runx1 as a Novel Tethering Factor in Receptor-Mediated Transcriptional Activation
J. Stender (2010)
10.1073/PNAS.96.16.9212
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.
C. Perou (1999)
10.1200/JCO.2006.07.1522
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
S. Loi (2007)
10.1038/bjc.1997.41
Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone.
R. Clarke (1997)
10.1200/JCO.2003.09.099
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
V. Bardou (2003)
10.1038/sj.bjc.6601831
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients
M. Stendahl (2004)
Insulin-like growth factor binding protein 2 is a Luminal B Breast Cancer www.jco.org © 2014 by American Society of Clinical Oncology
A Juncker-Jensen (2006)
10.1038/nature11143
Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition
M. Ellis (2012)
10.1186/1471-2164-7-96
The molecular portraits of breast tumors are conserved across microarray platforms
Z. Hu (2006)
10.1200/jco.2013.31.26_suppl.142
Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
G. Hortobagyi (2013)
10.1007/s10549-011-1488-0
Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics
E. Lips (2011)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1038/nrc3215
The insulin and insulin-like growth factor receptor family in neoplasia: an update
M. Pollak (2012)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.1200/JCO.2005.04.7985
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
S. Paik (2006)
10.4161/cbt.6.1.3549
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
Q. Zhou (2007)
10.3892/ijo.2013.1981
Altered expression of MLL methyltransferase family genes in breast cancer.
D. Rabello (2013)
10.1158/0008-5472.SABCS12-S5-6
Abstract S5-6: Activating HER2 mutations in HER2 gene amplification negative breast cancers.
R. Bose (2012)
10.1038/nature11412
Comprehensive molecular portraits of human breast tumors
D. Koboldt (2012)
10.1038/nrclinonc.2013.29
Emerging targeted agents in metastatic breast cancer
D. Zardavas (2013)
10.1200/JCO.2005.02.0818
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
L. Gianni (2005)
10.1200/JCO.2005.04.005
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
I. Smith (2005)
10.1200/JCO.2005.05.145
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.
M. Jansen (2005)
10.1158/1078-0432.CCR-04-2421
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
R. Rouzier (2005)
10.1186/bcr2113
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer
J. Lisztwan (2008)
10.1158/1078-0432.CCR-07-4122
Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy
M. Rudas (2008)
10.1371/journal.pone.0053292
PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
S. Loi (2013)
10.1007/s10549-008-9939-y
Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen
M. Kok (2008)
10.1073/pnas.0907011107
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer
S. Loi (2010)
10.1083/jcb.200403069
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
L. S. Harrington (2004)
319O: Significant antitumor activity of E-3810, a novel FGFR and VEGFR inhibitor, in patients with FGFR1 amplified breast cancer. Presented at the European Society for Medical Oncology
R Dienstmann (2012)
10.1016/S0140-6736(97)11423-4
Tamoxifen for early breast cancer: An overview of the randomised trials
O. Abe (1998)
10.1016/S1470-2045(09)70314-6
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
K. Albain (2010)
10.1093/jnci/djn309
Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
M. Ellis (2008)
10.1038/nature11154
Sequence analysis of mutations and translocations across breast cancer subtypes
S. Banerji (2012)
10.1200/JCO.2010.28.15_SUPPL.3008
A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.
S. Cosimo (2010)
10.1016/J.YONC.2012.08.009
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
J. Thigpen (2012)
10.1016/S0140-6736(97)11423-4
Tamoxifen for early breast cancer: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group (1998)
10.1158/1078-0432.CCR-07-5136
Targeting the MDM2-p53 Interaction for Cancer Therapy
S. Shangary (2008)
10.1016/j.molonc.2007.10.004
The MINDACT trial: The first prospective clinical validation of a genomic tool
F. Cardoso (2007)
10.1158/0008-5472.SABCS-09-106
A Meta-Analysis of Gene Expression Profiling Studies Identifies Clinically Relevant Oncogenic Pathways in Basal-Like Breast Cancer.
M. Ignatiadis (2009)
10.1159/000351193
St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion
N. Harbeck (2013)
10.1016/J.YPAT.2011.11.057
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
B. A. Carter (2012)
10.1158/0008-5472.CAN-07-2707
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
S. Massarweh (2008)
10.4161/cc.8.4.7659
Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy
A. Choo (2009)
10.1093/JNCI/DJJ052
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
C. Sotiriou (2006)
10.1371/journal.pcbi.1002240
Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome
D. Venet (2011)
10.1186/bcr2904
Luminal-B breast cancer and novel therapeutic targets
B. Tran (2011)
10.1158/0008-5472.CAN-05-2925
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Kathryn E. O'Reilly (2006)
10.1158/0008-5472.CAN-09-0042
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.
T. Miller (2009)
10.3816/CBC.2006.N.051
TAILORx: trial assigning individualized options for treatment (Rx).
J. Sparano (2006)
10.1200/JCO.2011.39.0708
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.
T. Bachelot (2012)
10.1158/0008-5472.CAN-07-5644
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
10.1002/emmm.201100122
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium
D. Holland (2011)
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
J. Gerdes (1984)
10.1093/annonc/mdu497
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
I. Treilleux (2015)
10.1093/ANNONC/MDT084.1
53O_PRPREDICTING RISK FOR LATE METASTASIS: THE PAM50 RISK OF RECURRENCE (ROR) SCORE AFTER 5 YEARS OF ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH HR+ EARLY BREAST CANCER: A STUDY ON 1,478 PATIENTS FROM THE ABCSG-8 TRIAL
M. Gnant (2013)
10.1056/NEJMOA052933
Concordance among gene-expression-based predictors for breast cancer.
C. Fan (2006)
10.1016/s0923-7534(20)32898-2
Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer
R. Dienstmann (2012)
10.1200/JCO.2007.12.2747
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
E. Rakha (2007)
10.1158/1078-0432.CCR-06-1109
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
L. Carey (2007)
10.1158/1078-0432.CCR-10-1282
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
T. Nielsen (2010)
10.1200/JCO.2009.24.4798
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
M. Dowsett (2010)
10.1038/nrc2780
Fibroblast growth factor signalling: from development to cancer
N. Turner (2010)
10.1186/bcr1399
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay
L. Perreard (2005)
10.1200/JCO.2012.43.4134
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.
A. Prat (2013)
10.1038/ng.2764
The Cancer Genome Atlas Pan-Cancer analysis project
J. Weinstein (2013)
Strategies for subtypes : d Dealing with the diversity of breast cancer — Highlights of the St . Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer
N Harbeck (2011)
10.1002/cncr.24876
Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy
R. Bhargava (2010)
10.1186/1755-8794-4-3
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures
C. Fan (2010)
10.1186/bcr1665
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
Somaia Elbauomy Elsheikh (2006)
10.1200/JCO.2008.18.8391
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
J. Baselga (2009)
10.1038/sj.bjc.6690112
Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line
J. Parisot (1999)
Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
M. Lv (2011)
10.1016/S1043-321X(08)80027-6
Ki-67 as Prognostic Marker in Early Breast Cancer: A Meta-analysis of Published Studies Involving 12 155 Patients
M. Gilcrease (2008)
10.1073/pnas.1732912100
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
C. Sotiriou (2003)
10.1038/sj.onc.1206818
Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer
P. Span (2003)
10.1200/JCO.2005.03.3845
Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
J. Brenton (2005)
10.1200/JCO.2008.18.1024
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
J. Hugh (2009)
10.1158/2159-8290.CD-12-0349
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
R. Bose (2013)
10.1200/JCO.2011.39.5624
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.
M. Ignatiadis (2012)
10.1200/JCO.2012.46.1558
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
M. Dowsett (2013)
10.1016/S0140-6736(11)61625-5
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
R. Peto (2012)
10.1093/jnci/djr393
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
M. Dowsett (2011)
10.1371/journal.pmed.1000279
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
F. Blows (2010)
10.1016/S0140-6736(07)60200-1
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. Coombes (2007)
10.1038/nature10983
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
C. Curtis (2012)
10.1172/JCI41680
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
T. Miller (2010)
10.1200/JCO.2011.29.15_SUPPL.TPS104
SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less.
A. González-Angulo (2011)
10.1309/HCF035N9WK40ETJ0
Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases.
L. Collins (2005)
10.1158/0008-5472.CAN-11-1080
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Xiaonan Hou (2011)
10.1016/J.EJCA.2007.10.003
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.
A. Awada (2008)
10.1007/s10549-009-0333-1
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
M. Straver (2009)
10.1200/jco.2009.27.18s.lba515
Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657).
L. Esserman (2009)
10.1016/S1470-2045(10)70008-5
Breast cancer molecular profiling with single sample predictors: a retrospective analysis.
B. Weigelt (2010)
10.1158/1535-7163.MCT-11-0963
Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
C. E. Caldon (2012)
10.1371/journal.pone.0009201
Delineating Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer Cell Lines
M. Kadota (2010)
10.1186/bcr2124
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
P. Wirapati (2008)
10.1016/0959-8049(93)90218-5
Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells.
L. R. Wiseman (1993)
10.1200/JCO.2005.23.16_SUPPL.510
Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer
S. Paik (2005)
Trans - lational studies within the TAMRAD randomized Gineco trial : Evidence for TORC 1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer ( MBC )
T Bachelot
10.1016/s0923-7534(19)65685-1
13O_PR Translational Studies Within the Tamrad Randomized Gineco Trial: Evidence for Torc1 Activation Marker as a Predictive Factor for Everolimus Efficacy in Metastatic Breast Cancer (MBC)
T. Bachelot (2012)



This paper is referenced by
Exploring the impact of anti-oestrogen resistance on the capacity of breast cancer cells to modulate bone cell function and their sensitivity to bisphosphonates
D. Lymperatou (2017)
10.2217/epi-2016-0015
H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes.
Gaëlle Judes (2016)
10.1080/03007995.2020.1783646
Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors
Shaheenah Dawood (2020)
Investigation of Ring Finger Protein 8 in Mammalian Physiology and Pathogenesis
L. Li (2015)
Prognostic and Predictive Markers in Primary Breast Cancer - Quality Assurance and Long-term Effects of Adjuvant tamoxifen Treatment
M. Ekholm (2018)
Review Article Breast cancer intrinsic subtype classification, clinical use and future trends
X. Dai (2015)
10.18632/oncotarget.14402
Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer
Huimei Yu (2017)
Breast cancer intrinsic subtype classification, clinical use and future trends.
X. Dai (2015)
10.1186/s13058-017-0888-4
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
E. Curtit (2017)
10.1186/s13058-020-01264-z
MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth
M. Li (2020)
10.1016/j.molonc.2015.10.013
An integrated genomic analysis of Tudor domain–containing proteins identifies PHD finger protein 20‐like 1 (PHF20L1) as a candidate oncogene in breast cancer
Y. Jiang (2016)
10.1093/nar/gkv922
Beyond the one-locus-one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity
A. G. Telonis (2015)
10.1158/1078-0432.CCR-19-0138
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer
Joshua Z Drago (2019)
10.1634/theoncologist.2016-0423
Association Study Confirmed Three Breast Cancer‐Specific Molecular Subtype‐Associated Susceptibility Loci in Chinese Han Women
Y. Xu (2017)
10.1007/s12672-016-0275-0
Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts
Shawna B. Matthews (2016)
10.1016/j.celrep.2018.12.071
p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value
Angela Santoro (2019)
10.1109/TCBB.2017.2679745
PerPAS: Topology-Based Single Sample Pathway Analysis Method
Chengyu Liu (2018)
10.1016/B978-0-323-35955-9.00055-6
Adjuvant and neoadjuvant systemic therapies for early-stage breast cancer
C. Santa-Maria (2018)
ROLE OF NON-MUSCLE MYOSIN IIB IN BREAST CANCER INVASION
D. Thomas (2016)
10.1056/NEJMc1708487
Adjuvant Capecitabine for Breast Cancer.
José I Ruades Ninfea (2017)
10.1038/npjbcancer.2015.16
Analyzing historical trends in breast cancer biomarker expression: a feasibility study (1947–2009)
N. Krieger (2015)
10.1371/journal.pone.0129741
Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women
S. Hao (2015)
10.1007/978-3-030-29286-7_13
Breast Cancer Precision Medicine in Hispanics/Latinas: Focus on Luminal B Tumors
J. Zabaleta (2020)
10.1016/j.cpet.2018.02.004
Molecular Classification of Breast Cancer.
E. Provenzano (2018)
10.1002/jcp.24891
Anthropometric, Metabolic and Molecular Determinants of Human Epidermal Growth Factor Receptor 2 Expression in Luminal B Breast Cancer
P. Vici (2015)
10.1002/cncr.30637
Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer
Elizabeth M Cespedes Feliciano (2017)
10.20471/acc.2018.57.03.04
PROGNOSTIC IMPACT OF LOW ESTROGEN AND PROGESTERONE POSITIVITY IN LUMINAL B (HER2 NEGATIVE) BREAST CANCER
Jasmina Rajc (2018)
10.1038/s41416-020-0821-y
Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma
Teppei Sugano (2020)
10.1007/978-3-319-17972-8_10
Prediction of Response to Aromatase Inhibitors in Breast Cancer
A. Larionov (2015)
10.1371/journal.pone.0133830
Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer
Y. Shao (2015)
Does loss of PRH alter the sensitivity of Dasatinib in breast tumour cells
Nirjit Mavi (2015)
10.1007/s10549-015-3423-2
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer
A. Rocca (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar